News
AI · Drug Discovery · Partnership · Pharmaceuticals
Novo Nordisk announced a strategic partnership with OpenAI to integrate advanced artificial intelligence across its operations, from drug discovery to commercial activities, aiming to analyze complex datasets, identify drug candidates, and reduce time from research to patient delivery, which caused Novo stock to gain roughly 2% in morning trade.
The Danish pharmaceutical company will leverage OpenAI's capabilities to enhance efficiency in manufacturing, supply chain, distribution, and corporate operations. This collaboration also includes upskilling Novo Nordisk’s global workforce and improving AI literacy across the company.
Mike Doustdar, President and CEO of Novo Nordisk, stated the partnership is a crucial step for the company to lead in the next era of healthcare, addressing the treatment needs of millions living with obesity and diabetes by enabling analysis of datasets at an unprecedented scale and faster hypothesis testing. Sam Altman, CEO of OpenAI, emphasized AI's role in reshaping industries and helping people live better, longer lives, noting the collaboration will accelerate scientific discovery and redefine patient care.
Pilot programs will launch across research, development, manufacturing, and commercial operations, with full integration planned by the end of 2026. The partnership builds on Novo Nordisk’s existing AI initiatives.
